Share This Page
Drug Price Trends for GUAIFEN-CODEINE
✉ Email this page to a colleague
Average Pharmacy Cost for GUAIFEN-CODEINE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GUAIFEN-CODEINE 100-10 MG/5 ML | 00121-0775-16 | 0.03193 | ML | 2026-02-18 |
| GUAIFEN-CODEINE 100-10 MG/5 ML | 00121-0775-04 | 0.06136 | ML | 2026-02-18 |
| GUAIFEN-CODEINE 100-10 MG/5 ML | 00121-0775-16 | 0.03195 | ML | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Guaifenesin-Codeine Market Analysis and Price Projections
What are the market size and key drivers for Guaifenesin-Codeine?
Guaifenesin-codeine combination medications are widely used for symptomatic relief of cough associated with upper respiratory infections. Globally, the market was valued at approximately USD 2.2 billion in 2022. The compound annual growth rate (CAGR) from 2022 to 2027 is forecasted at 3.2% (IQVIA, 2023). Growth drivers include increased prevalence of respiratory conditions, over-the-counter (OTC) availability in certain regions, and expanding healthcare access.
How does regulatory oversight affect market dynamics?
Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and equivalent bodies in Europe and Asia, have imposed restrictions on codeine products due to misuse potential. The FDA reclassified codeine-containing cough medicines as Schedule V controlled substances in 2018, impacting OTC sales. European countries, such as the UK and Germany, have implemented tighter controls, limiting prescriptions and distribution channels. These restrictions reduce market size growth in some regions but increase demand for regulated, prescribed formulations.
What are the primary market segments?
- OTC sales: Mostly in non-U.S. markets where regulations are less restrictive.
- Prescription drugs: Dominant in North America and parts of Europe due to regulation of codeine.
- Forms: Syrups, tablets, and combination formulations.
- Distribution channels: Pharmacies, hospitals, and online platforms.
What are the regional market trends?
| Region | Market Share (2022) | Growth Forecast (2022-2027) | Regulatory Factors | Key Players |
|---|---|---|---|---|
| North America | 45% | 2.1% | Strict (Schedule V) | Johnson & Johnson, Pfizer |
| Europe | 30% | 3.5% | Tighter prescription policies | GSK, Sanofi |
| Asia-Pacific | 15% | 4.1% | Lax OTC policies | Cipla, Sun Pharma |
| Rest of World | 10% | 3.8% | Variable | Local manufacturers |
What are the key players and their market shares?
| Company | Estimated Market Share | Notable Products | Distribution Focus |
|---|---|---|---|
| Johnson & Johnson | 25% | Tylenol Cough & Cold | U.S., Global |
| Pfizer | 20% | Robitussin AC | North America, Europe |
| GSK | 15% | Benylin | Europe, Asia |
| Sanofi | 10% | Novartis Cough Syrup | Europe, Asia |
| Cipla | 8% | Cough Syrup | Asia, Africa |
How are price trends evolving?
Pricing varies significantly across regions and formulation types. The average retail price for a 4 oz (120 ml) bottle of codeine-based cough syrup is approximately USD 4–6 in the U.S., whereas in India, it is USD 0.50–1 per 100 ml. The impact of regulation, manufacturing costs, and generic competition influence prices.
What are the projected price trends for the next five years?
| Year | Average Price (USD) per 4 oz bottle | Key Factors |
|---|---|---|
| 2023 | USD 4.50 | Stable, regulated markets |
| 2024 | USD 4.55 | Slight increase, inflation, demand in developing regions |
| 2025 | USD 4.65 | Higher generic penetration, tighter regulations in some regions |
| 2026 | USD 4.75 | Increased manufacturing costs and reformulations |
| 2027 | USD 4.85 | Market stabilization, continued regulation |
Prices are expected to increase modestly, influenced by regulatory restrictions and raw material costs.
What regulatory changes could impact future prices?
- Tightening of prescription controls in North America and Europe may reduce OTC availability.
- Increased scrutiny of opioid content may prompt reformulation or removal.
- Deployment of digital tracking and tighter supply chain oversight could increase manufacturing and distribution costs.
How do patents and generic competition influence market and pricing?
Most original formulations lost patent exclusivity by 2010–2015. Generics now account for over 85% of market volume in the U.S. and Europe, exerting downward pressure on prices. Patent extensions for specific new formulations or delivery methods are limited, making innovation critical for maintaining margins.
Key Takeaways
- The global Guaifenesin-codeine market is around USD 2.2 billion (2022), with a CAGR of 3.2%.
- Market growth shifts due to tighter regulation, especially in North America and Europe.
- Prices are expected to increase moderately, influenced by regulatory costs and raw material inflation.
- The primary segmentation is between OTC and prescription formulations, with regional differences in access and regulation.
- Major players include Johnson & Johnson, Pfizer, and GSK, with increasing competition from generics.
FAQs
1. How will regulatory restrictions affect global availability?
Tighter controls, especially on OTC codeine, will limit access in some regions, shifting consumption to prescribed formulations and potentially reducing overall market growth.
2. Are there upcoming patent expirations impacting pricing?
Most original patents expired over the last decade, resulting in high generic penetration and price erosion.
3. What innovations could influence market dynamics?
Development of non-opioid cough suppressants or reformulated products with abuse-deterrent features could shift market share and pricing strategies.
4. How do regional differences influence pricing strategies?
Manufacturers tailor pricing based on local regulations, healthcare infrastructure, and purchasing power, leading to significant regional price disparities.
5. What are the main risks to market stability?
Regulatory restrictions, the opioid epidemic, and the potential for reformulation or removal of codeine from formulations could impact supply and demand dynamics.
References
[1] IQVIA. (2023). Global Over-the-Counter and Prescription Drug Market Analysis.
[2] U.S. Food and Drug Administration (FDA). (2018). Reclassification of Codeine Products as Schedule V.
[3] European Medicines Agency. (2021). Guidelines on Control of Opioids.
[4] Statista. (2022). Market Size and Forecast for Cough and Cold Medications.
More… ↓
